A Study to Assess the Tolerability of Oxylanthanum Carbonate in Patients With Chronic Kidney Disease on Dialysis

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 106 participants.

Also called NCT06218290

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 106 participants (enrolled count) (from the registry)
Sponsor
Unicycive Therapeutics, Inc (from the registry)
Registry
  • NCT NCT06218290
Other papers using this trial's data
  • Two-Way Randomized Crossover Study to Establish Pharmacodynamic Bioequivalence Between Oxylanthanum Carbonate and Lanthanum Carbonate Clinical therapeutics, 2025-01 DOI, PubMed 39617673

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06218290. Allocation not applicable; no masking; primary purpose treatment. Start 2023-12-15 (actual); primary completion 2024-05-29 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Assess the Tolerability of Oxylanthanum Carbonate in Patients With Chronic Kidney Disease on Dialysis
Condition
Chronic Kidney Disease Requiring Chronic Dialysis
Intervention (Drug)
Oxylanthanum Carbonate
Lead sponsor
Unicycive Therapeutics, Inc (class: industry)

Record details

Record id
cardio:ct-nct06218290
Content hash
4fbfcb2e87b507ff4ad9496c720d5b911cd0fef95de2d31003a918b14e249c2f